Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CNS

- PMLiVE

Sanofi, Regeneron’s Libtayo shows marked reduction in risk of death in cervical cancer patients

Phase 3 trial showed drug reduced the risk of death by 31% compared to chemotherapy

regeneron headquarters

UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’

CHMP has now adopted a positive opinion for the treatment

- PMLiVE

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda

regeneron headquarters

EMA launches rolling review of Regeneron’s COVID-19 antibody cocktail

Study suggests REGN-COV2 can reduce viral load in non-hospitalised patients with COVID-19

regeneron headquarters

Regeneron’s antibody cocktail prevents COVID-19 in high-risk patients

Monoclonal antibodies prevented 100% of symptomatic infections

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Drug approved to treat high-risk patients with mild to moderate COVID-19

- PMLiVE

Regeneron halts enrolment of severely ill patients in COVID-19 antibody trial

Trial modified based on recommendations from independent data monitoring committee

Podcast

Living With Chronic Illness (Series one)

Research Partnership

- PMLiVE

Regeneron scores first FDA approval for Ebola antibody treatment

Treatment cut mortality rate in study based in the Democratic Republic of Congo

- PMLiVE

Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail

If approved, the US government will make initial doses available at no cost

- PMLiVE

Regeneron’s COVID-19 antibody cocktail reduces viral load and alleviates symptoms

Investigational treatment also helped patients recover faster

- PMLiVE

Regeneron launches phase 3 COVID-19 antibody trial in the UK

Drug cocktail will be evaluated in patients hospitalised with COVID-19

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links